Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V. Miglietta F, et al. Among authors: guarneri v. Oncologist. 2020 Sep;25(9):e1355-e1362. doi: 10.1634/theoncologist.2020-0201. Epub 2020 Jul 21. Oncologist. 2020. PMID: 32618068 Free PMC article.
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Bengala C, Pazzagli I, Innocenti F, Donati S, Favre C, Menconi MC, Greco F, Danesi R, Orlandini C, Guarneri V, Del Tacca M, Conte PF. Bengala C, et al. Among authors: guarneri v. Ann Oncol. 2001 Jan;12(1):69-74. doi: 10.1023/a:1008302402687. Ann Oncol. 2001. PMID: 11249051 Free article. Clinical Trial.
New combinations with epirubicin in advanced breast cancer.
Conte P, Gennari A, Landucci E, Guarneri V, Donati S, Salvadori B, Bengala C, Orlandini C. Conte P, et al. Among authors: guarneri v. Oncology (Williston Park). 2001 May;15(5 Suppl 7):24-7. Oncology (Williston Park). 2001. PMID: 11396361 Free article. Review.
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C, Danesi R, Guarneri V, Pazzagli I, Donati S, Favre C, Fogli S, Biadi O, Innocenti F, Del Tacca M, Mariani M, Conte PF. Bengala C, et al. Among authors: guarneri v. Bone Marrow Transplant. 2003 Feb;31(4):275-80. doi: 10.1038/sj.bmt.1703827. Bone Marrow Transplant. 2003. PMID: 12621462
High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).
Bengala C, Guarneri V, Ledermann J, Rosti G, Wandt H, Lotz JP, Cure JH, Orlandini C, Ferrante P, Conte PF, Demirer T; EBMT Solid Tumor Working Party. Bengala C, et al. Among authors: guarneri v. Bone Marrow Transplant. 2005 Jul;36(1):25-31. doi: 10.1038/sj.bmt.1705007. Bone Marrow Transplant. 2005. PMID: 15908977
Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
Conte PF, Donati S, Gennari A, Guarneri V, Orlandini C, Rondini M, Roncella M, Marini L, Collecchi P, Viacava P, Naccarato AG, Degli Esposti R, Bonardi S, Bottini A, Saracchini S, Tumolo S, Gullo G, Santoro A, Crino L. Conte PF, et al. Among authors: guarneri v. Br J Cancer. 2005 Aug 22;93(4):406-11. doi: 10.1038/sj.bjc.6602723. Br J Cancer. 2005. PMID: 16052214 Free PMC article. Clinical Trial.
300 results